Corvus to Host Investor Meeting on Soquelitinib Data; Q1 Results May 7

Corvus Pharmaceuticals announced it will host an investor and analyst meeting on May 14, 2026, to highlight new immunologic and biomarker data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. This data, which supports the potential for drug-free remissions, will also be presented in two oral sessions at the Society for Investigative Dermatology (SID) Annual Meeting on May 14 and May 16, 2026. Additionally, the company plans to report its first quarter 2026 financial results in a press release on May 7, 2026, without an accompanying conference call.